DK173859B1 - Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner - Google Patents

Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner Download PDF

Info

Publication number
DK173859B1
DK173859B1 DK198805877A DK587788A DK173859B1 DK 173859 B1 DK173859 B1 DK 173859B1 DK 198805877 A DK198805877 A DK 198805877A DK 587788 A DK587788 A DK 587788A DK 173859 B1 DK173859 B1 DK 173859B1
Authority
DK
Denmark
Prior art keywords
factor
process according
buffer
fraction
sodium chloride
Prior art date
Application number
DK198805877A
Other languages
Danish (da)
English (en)
Other versions
DK587788A (da
DK587788D0 (da
Inventor
Thierry Burnouf
Catherine Michalski
Original Assignee
Ct Regional De Transfusion San
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26226280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK173859(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8714665A external-priority patent/FR2622108B1/fr
Priority claimed from FR8806923A external-priority patent/FR2631830B1/fr
Application filed by Ct Regional De Transfusion San filed Critical Ct Regional De Transfusion San
Publication of DK587788D0 publication Critical patent/DK587788D0/da
Publication of DK587788A publication Critical patent/DK587788A/da
Application granted granted Critical
Publication of DK173859B1 publication Critical patent/DK173859B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DK198805877A 1987-10-23 1988-10-21 Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner DK173859B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8714665A FR2622108B1 (fr) 1987-10-23 1987-10-23 Preparation de concentres de proconvertine (facteur vii), de facteur antihemophilique b (facteur ix) et d'autres proteines plasmatiques, et leur utilisation therapeutique
FR8714665 1987-10-23
FR8806923 1988-05-25
FR8806923A FR2631830B1 (fr) 1988-05-25 1988-05-25 Concentre de facteur ix de haute purete, sa preparation et son utilisation en therapeutique

Publications (3)

Publication Number Publication Date
DK587788D0 DK587788D0 (da) 1988-10-21
DK587788A DK587788A (da) 1989-04-24
DK173859B1 true DK173859B1 (da) 2001-12-31

Family

ID=26226280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198805877A DK173859B1 (da) 1987-10-23 1988-10-21 Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner

Country Status (8)

Country Link
US (1) US5457181A (de)
EP (1) EP0317376B2 (de)
JP (1) JP2768957B2 (de)
DE (1) DE3877529T2 (de)
DK (1) DK173859B1 (de)
ES (1) ES2045167T5 (de)
GR (2) GR3006910T3 (de)
NO (1) NO179997C (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914869C1 (de) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
DE69130990T2 (de) * 1990-02-20 1999-12-02 Baxter International Inc., Deerfield Gereinigtes, virusfreies menschliches Thrombin
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
CA2105282C (en) 1991-03-01 2002-09-24 Centeon L.L.C. Preparation of factor ix
FR2711371B1 (fr) * 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4406515C1 (de) * 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
ES2127695B1 (es) * 1997-02-14 2000-03-16 Grifols Grupo Sa Procedimiento para la reduccion del contenido de factor plaquetar 4 en proteinas plasmaticas que poseen afinidad a heparina.
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
SE0203551D0 (sv) * 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
US20040106779A1 (en) * 2002-12-03 2004-06-03 Bigler Douglas E. Modified factor IX preparation
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ｉｘ因子調製物およびその精製方法
WO2005058283A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
JP5037331B2 (ja) * 2004-03-19 2012-09-26 バクスター・インターナショナル・インコーポレイテッド 出血性障害の処置のための第ｉｘａ因子
KR100667860B1 (ko) * 2005-10-18 2007-01-11 주식회사 녹십자 고순도 사람 혈액응고 제9인자의 정제 방법
CL2007002615A1 (es) * 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
WO2008104372A1 (en) * 2007-02-28 2008-09-04 Baxter International Inc. Method for the purification of recombinant blood coagulation factor ix enriched in sulfated and/or phosphorylated molecules
ES2595059T3 (es) 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
RU2649363C2 (ru) * 2010-11-16 2018-04-02 Октафарма Аг СПОСОБЫ СНИЖЕНИЯ И/ИЛИ УДАЛЕНИЯ FXI и FXIa ИЗ РАСТВОРОВ, СОДЕРЖАЩИХ УКАЗАННЫЕ ФАКТОРЫ СВЕРТЫВАНИЯ
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
PL2748179T3 (pl) 2011-10-14 2022-04-11 Takeda Pharmaceutical Company Limited Oczyszczanie białka metodą anionowej chromatografii jonowymiennej
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
GB201506117D0 (en) * 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
CN110339209B (zh) * 2019-07-18 2023-06-06 上海泰坦科技股份有限公司 一种去甲状腺结合蛋白的小牛血清的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2459291C3 (de) * 1974-12-14 1981-06-04 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3172210D1 (en) * 1980-05-27 1985-10-17 Miles Lab Blood coagulation promoting product and process of preparing same
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4397841A (en) * 1982-06-28 1983-08-09 Monsanto Company Production of blood coagulation factor VIII:C
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
CA1288711C (en) * 1986-01-06 1991-09-10 Kenneth J. Smith Therapeutic blood product means and methods of preparing same

Also Published As

Publication number Publication date
JP2768957B2 (ja) 1998-06-25
EP0317376A1 (de) 1989-05-24
NO884688D0 (no) 1988-10-21
DK587788A (da) 1989-04-24
JPH01207239A (ja) 1989-08-21
GR3019900T3 (en) 1996-08-31
EP0317376B1 (de) 1993-01-13
DE3877529D1 (de) 1993-02-25
EP0317376B2 (de) 1996-04-03
DK587788D0 (da) 1988-10-21
DE3877529T2 (de) 1996-11-07
ES2045167T3 (es) 1994-01-16
US5457181A (en) 1995-10-10
NO179997C (no) 1997-01-29
NO179997B (no) 1996-10-21
NO884688L (no) 1989-04-24
GR3006910T3 (en) 1993-06-30
ES2045167T5 (es) 1996-07-01

Similar Documents

Publication Publication Date Title
DK173859B1 (da) Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner
US5854403A (en) Method for isolation of highly pure von Willebrand Factor
US4877866A (en) Method of producing a virus safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation
US5344918A (en) Process for the manufacture of a high-purity activated factor VII concentrate essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg
US4877608A (en) Pharmaceutical plasma protein formulations in low ionic strength media
US4272523A (en) Fractionating citrate-stabilized plasma
US4495175A (en) Preparation of highly purified human antihemophilic factor
CA2024667C (en) Process for preparing a concentrate of blood coagulation factor viii-von willebrand factor complex from total plasma
US4470969A (en) Process for producing a concentrate of coagulation factors VII and VIIa
DK164282B (da) Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem
US7648958B2 (en) Factor VIII/vWF-complex and methods of purifying same
US4749783A (en) Viral inactivation and purification of active proteins
US5252217A (en) Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
JPH0580455B2 (de)
JPH0424360B2 (de)
US6063909A (en) Preparation of factor IX
US4473553A (en) Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa
KR100667860B1 (ko) 고순도 사람 혈액응고 제9인자의 정제 방법
Josic et al. Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography
JP3043558B2 (ja) ヒト活性化プロテインｃ調製物及びその製法
EP0245875A2 (de) Verfahren zur Reinigung von Faktor-VIII
Wickerhauser et al. A Single‐Step Method for the Isolation of Antithrombin III 1, 2
EP0650364B1 (de) Reinigung von faktor ix
US20040106779A1 (en) Modified factor IX preparation
de Lille llllll" 111 ill Ilill ll| l| lllll lllll|||| l lilil lllll| l|||" II" III lllll| ll|

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired